

Date: 10th November, 2021

BSE Limited Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404 National Stock Exchange of India Limited Listing Department Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051. Symbol: MARKSANS

Sub: Statement on Deviation or Variation of funds raised through Preferential Issue of Convertible Warrants.

Dear Sir,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDI/162/2019 dated December 24, 2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021.

Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended September 30, 2021 is given in "Annexure A".

You are requested to note the above in your records.

Thanking You.

Yours faithfully, For Marksans Pharma Limited

Harshavardhan Panigrahi Company Secretary

Encl: As above

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com www.marksanspharma.com

Statement of Deviation or Variation for the quarter ended 30th September, 2021

Statement of Deviation / Variation in utilisation of funds raised				
Name of listed entity	Marksans Pharma Limited			
Mode of Fund Raising	Preferential Issue			
Date of Raising Funds	20.07.2021			
Amount Raised	Rs. 93,09,99,994			
Report filed for quarter ended	30 th September, 2021			
Monitoring Agency	Not Applicable			
Monitoring Agency Name, if applicable	Not Applicable			
Is there a Deviation / Variation in use of funds raised	No			
If yes, whether the same is pursuant to change in terms	Not Applicable			
of a contract or objects, which was approved by the				
shareholders				
If Yes, Date of shareholder Approval	Not Applicable			
Explanation for the Deviation / Variation	Not Applicable			
Comments of the Audit Committee after review	Nil			
	Nil			
Comments of the auditors, if any				

Objects for which funds have been raised and where there has been a deviation, in the following table

table Original Object	Modified Object, if any	Original Allocation	Modifie d allocati on, if any	Funds utilised till 30 th September, 2021	Amount of deviation/va riation for the quarter according to applicable object	Remarks if any
The proceeds of the preferential issue are proposed to be used to strengthen the capital base and to enhance long term financial resources of the Company in order to fund expansion program of the Company.	None	Rs. 93,09,99,994	None	Rs. 93,09,90,041	Nil	No deviations

Ph MUMBAI-53 B Claury m

Deviation or variation could mean:

- Deviation in the objects or purposes for which the funds have been raised or **(a)**
- Deviation in the amount of funds actually utilized as against what was originally disclosed or **(b)**
- Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter (c) of offer, etc

For Marksans Pharma Limited



Harshavardhan Panigrahi Company Secretary & Compliance Officer